UPDATE 1-Sun Pharma Q2 net falls on US unit woes, Cipla soars

* Sun net profit at 4.54 bln rupees vs forecast of 3.77 bln

* Sun says U.S. unit working to gain compliance after seizure

* Cipla net up 83 pct to 2.76 bln rupees; f'cast was 2.86 bln

* Sun shares rise 0.9 pct, Cipla gain 1.6 pct in weak market (Adds details)

BANGALORE, Oct 28 (Reuters) - India's Sun Pharmaceutical Industries (SUN.BO) posted a smaller-than-expected 11.5 percent drop in quarterly profit as the seizure of its U.S. unit's drugs by the regulator on manufacturing violations weighed.

Cipla Ltd (CIPL.BO), another drugmaker, saw its net profit jump 83 percent in the September quarter on a rise in domestic and export earnings and foreign exchange gains.

Chairman Dilip Shanghvi said Sun's U.S. unit, Caraco Pharmaceutical Laboratories (CPD.A), was working towards full regulatory compliance to allow it to resume manufacturing.

In June, U.S. authorities seized all medicines made by generic drugmaker Caraco after health officials said there had been repeated violations of manufacturing standards.

Detroit-based Caraco signed a consent decree with the U.S. Food and Drug Administration in September, under which it cannot resume manufacturing until it gets a written notification from independent experts and the agency to do so.